Market Cap 11.20M
Revenue (ttm) 10.91M
Net Income (ttm) -43.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -397.71%
Debt to Equity Ratio 0.00
Volume 279,600
Avg Vol 287,490
Day's Range N/A - N/A
Shares Out 13.74M
Stochastic %K 6%
Beta 3.02
Analysts Strong Sell
Price Target $11.00

Company Profile

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 503 6500
Address:
Building C, Suite 500 128 Spring Street, Lexington, United States
LodiDodiWeLikesToParty
LodiDodiWeLikesToParty Mar. 21 at 3:52 AM
$CRIS without FDA approval, there is no drug. Zero mention of that happening. Endless trials and money raising to pay for the salaries of these clowns, meanwhile the stock price has fell for the past 5 years. Ridiculous.
0 · Reply
TheFinalBet
TheFinalBet Mar. 19 at 10:12 PM
$CRIS looking good
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 9:57 PM
$CRIS Q4 '25 Earnings Results & Recap Curis believes its cash and cash equivalents, plus $20.2M from January 2026 PIPE financing and up to an additional $20.2M from Series B Warrants, should fund operations into the second half of 2027.
0 · Reply
HedgeFundMgr
HedgeFundMgr Mar. 19 at 8:42 PM
$CRIS This is a good one to load up on and hold for a while. Don't freak the pumps or the dumps, buy as you can.
0 · Reply
mikesterz7
mikesterz7 Mar. 19 at 8:17 PM
$CRIS For the year ended December 31, 2025, Curis reported a net loss of $7.6 million, or $0.58 per share on both a basic and diluted basis, as compared to a net loss of $43.4 million, or $6.88 per share on both a basic and diluted basis in 2024. For the fourth quarter of 2025, Curis reported net income of $19.4 million or $1.23 per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024.
2 · Reply
Topzero
Topzero Mar. 19 at 3:17 PM
$CRIS tomorrow 5$ 100%
2 · Reply
UCD_12dd
UCD_12dd Mar. 18 at 4:27 AM
0 · Reply
UCD_12dd
UCD_12dd Mar. 18 at 4:24 AM
$CRIS i’ve been in this stock for over a decade… Why does everyone always get so excited about earnings? They don’t have any. I’m just waiting around for FDA approval… 
1 · Reply
Yodalay
Yodalay Mar. 16 at 5:16 PM
$CRIS March 19, Q4 results and con call. They must have some plan/strategy, they keep convincing NASDAQ to stay listed, and institutions keep adding. Wish they would convince me. Still holding a few here, underwater.
0 · Reply
BirdOnAWire
BirdOnAWire Mar. 16 at 4:40 PM
$CRIS Bye bye money.....again. Hopefully we get some much needed good news this week, or we are done.
0 · Reply
Latest News on CRIS
Curis Provides Fourth Quarter 2025 Business Update

Mar 19, 2026, 4:00 PM EDT - 1 day ago

Curis Provides Fourth Quarter 2025 Business Update


Curis to Present at Upcoming 30th Annual SNO Meeting

Nov 14, 2025, 9:26 AM EST - 4 months ago

Curis to Present at Upcoming 30th Annual SNO Meeting


Curis Provides Third Quarter 2025 Business Update

Nov 6, 2025, 4:00 PM EST - 4 months ago

Curis Provides Third Quarter 2025 Business Update


Curis to Present at Upcoming Healthcare Conferences in September

Sep 2, 2025, 10:43 AM EDT - 7 months ago

Curis to Present at Upcoming Healthcare Conferences in September


Curis Provides Second Quarter 2025 Business Update

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Curis Provides Second Quarter 2025 Business Update


Curis Provides First Quarter 2025 Business Update

May 6, 2025, 8:00 AM EDT - 11 months ago

Curis Provides First Quarter 2025 Business Update


Curis to Present at Upcoming Healthcare Conference in April

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Curis to Present at Upcoming Healthcare Conference in April


Curis Provides Fourth Quarter 2024 Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Curis Provides Fourth Quarter 2024 Business Update


Curis Announces Additional Data from TakeAim Leukemia Study

Dec 10, 2024, 8:00 AM EST - 1 year ago

Curis Announces Additional Data from TakeAim Leukemia Study


Curis Provides Third Quarter 2024 Business Update

Nov 14, 2024, 8:00 AM EST - 1 year ago

Curis Provides Third Quarter 2024 Business Update


Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer


Curis to Present at Upcoming Healthcare Conference in July

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Curis to Present at Upcoming Healthcare Conference in July


Curis to Present Updated Data from the TakeAim Leukemia Study

May 10, 2024, 8:00 AM EDT - 2 years ago

Curis to Present Updated Data from the TakeAim Leukemia Study


Curis Provides First Quarter 2024 Business Update

May 7, 2024, 8:00 AM EDT - 2 years ago

Curis Provides First Quarter 2024 Business Update


Curis to Present at Upcoming Healthcare Conferences in April

Apr 4, 2024, 7:30 AM EDT - 2 years ago

Curis to Present at Upcoming Healthcare Conferences in April


Curis Provides Fourth Quarter 2023 Business Update

Feb 8, 2024, 8:00 AM EST - 2 years ago

Curis Provides Fourth Quarter 2023 Business Update


Curis Announces Three Presentations at ASH

Dec 6, 2023, 8:00 AM EST - 2 years ago

Curis Announces Three Presentations at ASH


Curis's stock rises as analysts see ‘the next Pharmacyclics'

Nov 17, 2023, 9:04 AM EST - 2 years ago

Curis's stock rises as analysts see ‘the next Pharmacyclics'


Curis Provides Third Quarter 2023 Business Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Curis Provides Third Quarter 2023 Business Update


Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Sep 12, 2023, 8:00 AM EDT - 2 years ago

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer


Curis Provides Second Quarter 2023 Business Update

Aug 3, 2023, 4:01 PM EDT - 2 years ago

Curis Provides Second Quarter 2023 Business Update


Curis Announces $15.1 Million Registered Direct Offering

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Curis Announces $15.1 Million Registered Direct Offering


Curis Provides First Quarter 2023 Business Update

May 4, 2023, 4:01 PM EDT - 3 years ago

Curis Provides First Quarter 2023 Business Update


Curis Provides Fourth Quarter 2022 Business Update

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Curis Provides Fourth Quarter 2022 Business Update


LodiDodiWeLikesToParty
LodiDodiWeLikesToParty Mar. 21 at 3:52 AM
$CRIS without FDA approval, there is no drug. Zero mention of that happening. Endless trials and money raising to pay for the salaries of these clowns, meanwhile the stock price has fell for the past 5 years. Ridiculous.
0 · Reply
TheFinalBet
TheFinalBet Mar. 19 at 10:12 PM
$CRIS looking good
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 9:57 PM
$CRIS Q4 '25 Earnings Results & Recap Curis believes its cash and cash equivalents, plus $20.2M from January 2026 PIPE financing and up to an additional $20.2M from Series B Warrants, should fund operations into the second half of 2027.
0 · Reply
HedgeFundMgr
HedgeFundMgr Mar. 19 at 8:42 PM
$CRIS This is a good one to load up on and hold for a while. Don't freak the pumps or the dumps, buy as you can.
0 · Reply
mikesterz7
mikesterz7 Mar. 19 at 8:17 PM
$CRIS For the year ended December 31, 2025, Curis reported a net loss of $7.6 million, or $0.58 per share on both a basic and diluted basis, as compared to a net loss of $43.4 million, or $6.88 per share on both a basic and diluted basis in 2024. For the fourth quarter of 2025, Curis reported net income of $19.4 million or $1.23 per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024.
2 · Reply
Topzero
Topzero Mar. 19 at 3:17 PM
$CRIS tomorrow 5$ 100%
2 · Reply
UCD_12dd
UCD_12dd Mar. 18 at 4:27 AM
0 · Reply
UCD_12dd
UCD_12dd Mar. 18 at 4:24 AM
$CRIS i’ve been in this stock for over a decade… Why does everyone always get so excited about earnings? They don’t have any. I’m just waiting around for FDA approval… 
1 · Reply
Yodalay
Yodalay Mar. 16 at 5:16 PM
$CRIS March 19, Q4 results and con call. They must have some plan/strategy, they keep convincing NASDAQ to stay listed, and institutions keep adding. Wish they would convince me. Still holding a few here, underwater.
0 · Reply
BirdOnAWire
BirdOnAWire Mar. 16 at 4:40 PM
$CRIS Bye bye money.....again. Hopefully we get some much needed good news this week, or we are done.
0 · Reply
LodiDodiWeLikesToParty
LodiDodiWeLikesToParty Mar. 13 at 3:25 AM
$CRIS No product. No news. Nothing. No profits. No FDA talk at all.
0 · Reply
BallWasher69
BallWasher69 Mar. 12 at 8:31 PM
$CRIS will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.
2 · Reply
CaysonChang
CaysonChang Mar. 6 at 6:15 PM
1 · Reply
halabatush
halabatush Mar. 5 at 10:49 PM
$CRIS is the earning call today?
0 · Reply
rapidtrades
rapidtrades Mar. 5 at 2:53 PM
$CRIS 😃
0 · Reply
rapidtrades
rapidtrades Mar. 4 at 8:06 PM
$CRIS Joined the party folks !
1 · Reply
LandSharrk
LandSharrk Mar. 3 at 4:37 AM
$CRIS actually nothing bro
0 · Reply
NachoBusiness
NachoBusiness Feb. 27 at 9:11 PM
$CRIS 5k at 1.14 AH I’m in
2 · Reply
Unburdened
Unburdened Feb. 27 at 1:56 PM
$CRIS I thought earnings were today. I don't see a press release. Anyone see one? TY
0 · Reply
UCD_12dd
UCD_12dd Feb. 27 at 3:19 AM
$CRIS “this one goes to 11”
2 · Reply
Unburdened
Unburdened Feb. 24 at 2:50 PM
$CRIS On the road to 2...
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 1:31 PM
$CRIS RSI: 64.79, MACD: 0.0341 Vol: 0.09, MA20: 0.99, MA50: 1.02 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply